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Angiotensin (1-7) (Ang (1-7)) causes vasodilator eﬀects in Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHRs)
via angiotensin type 2 receptors (AT2R). However, the role of vascular AT2R in aging is not known. Therefore, we examined the
eﬀectofagingonAng(1-7)-mediatedvasodepressoreﬀectsandvascularangiotensinreceptorlocalizationinaging.Bloodpressure
was measured in conscious adult (∼17 weeks) and aged (∼19 months) normotensive rats that received drug combinations in
a randomised fashion over a 4-day protocol: (i) Ang (1-7) alone, (ii) AT1R antagonist, candesartan, alone, (iii) Ang (1-7) and
candesartan, or (iv) Ang-(1-7), candesartan, and the AT2R antagonist, PD123319. In a separate group of animals, the speciﬁc
MasR antagonist, A779, was administered in place of PD123319. Receptor localisation was also assessed in aortic sections from
adult and aged WKY rats by immunoﬂuorescence. Ang (1-7) reduced blood pressure (∼15mmHg) in adult normotensive rats
although this eﬀect was dependant on the background dose of candesartan. This depressor eﬀect was reversed by AT2Rb l o c k a d e .
In aged rats, the depressor eﬀect of Ang (1-7) was evident but was now inhibited by either AT2Rb l oc k a d eo rMasRb l oc k ad e .A tt h e
same time, AT2R, MasR, and ACE2 immunoreactivity was markedly elevated in aortic sections from aged animals. These results
indicate that the Ang (1-7)-mediated depressor eﬀect was preserved in aged animals. Whereas Ang (1-7) eﬀects were mediated
exclusively via stimulation of AT2R in adult WKY, with aging the vasodepressor eﬀect of Ang (1-7) involved both AT2Ra n dMasR.
1.Introduction
It is well known that Angiotensin II (Ang II) mediates its
physiological functions via two main receptor subtypes, the
type1(AT1R)andtype2(AT2R)angiotensinreceptorswhere
it has similar aﬃnity for both the AT1Ra n dA T 2R. However,
there is now increasing evidence suggesting that angiotensin
peptides other than Ang II can evoke cardiovascular eﬀects
that oppose the eﬀects mediated by the AT1Rv i aan u m b e r
of non-AT1R mechanisms. In fact, heptapeptide Angiotensin
(1-7), (Ang (1-7)), a biologically active metabolite of
angiotensin I (Ang I) and Ang II [1, 2] has been shown
to possess biological activity in its own right [3]. Interest
in Ang (1-7) has surged since the discovery of angiotensin
converting enzyme type 2 (ACE2) and recognition that Ang
(1-7) can be produced directly from Ang II via ACE2 [1, 2].
Although,Ang(1-7)diﬀerstoAngIIbyonlyoneaminoacid,
Ang (1-7)-mediated eﬀects are markedly diﬀerent to those
of Ang II, and it has been suggested that Ang (1-7) may in
fact play a counterregulatory role to Ang II [4], mediating a
range of eﬀects such as vasodilatation, inhibition of vascular
smoothmuscleproliferation,andﬂuidandelectrolytehome-
ostasis [5]. The cardiovascular eﬀects of Ang (1-7) are often
reported to be inhibited by the D-Ala
7 Ang (1-7) analogue,
known as A779 [6]. Recently, Ang (1-7) was identiﬁed as
an endogenous ligand for the Ang (1-7)/MasR( MasR),
since Ang (1-7)-mediated vasorelaxation was impaired in
MasR
−/− mice[7].However,undersomecircumstances,Ang
(1-7) can mediate its eﬀects via AT2R[ 8–10]. In fact, we
have shown that Ang (1-7)-mediated vasodepressor eﬀect
was via an AT2R sensitive pathway [11]. In that study,
Ang (1-7) acutely lowered blood pressure in spontaneously
hypertensive rats (SHRs) and Wistar-Kyoto (WKY) adult
rats during concomitant AT1R blockade, [11] in a similar
manner to that seen with AT2R agonist, CGP42114 [12, 13],
and more recently with selective nonpeptide AT2R agonist,2 International Journal of Hypertension
Table 1: Resting MAP recorded on separate days before drug treatments, as indicated.
Treatment MAP (mmHg)
Group 1 (n = 4)
Saline 132 ± 14
Ang-(1-7) (15pmol/kg/min) 124 ± 4
Candesartan (0.01mg/kg) 131 ± 6
Ang-(1-7) and candesartan 134 ± 4
Group 2 (n = 7)
Saline 131 ± 13
Ang-(1-7) (15pmol/kg/min) 136 ± 13
Candesartan (0.01mg/kg) 126 ± 15
Ang-(1-7) and candesartan 136 ± 16
Group 3 (n = 6)
Ang-(1-7) (15pmol/kg/min) 138 ± 8
Candesartan (0.1mg/kg) 135 ± 8
Ang-(1-7) and candesartan 139 ± 11
Ang-(1-7), candesartan, and PD123319 (50µg/kg/min) 139 ± 5
Group 4 (n = 7)
Ang-(1-7) (15pmol/kg/min) 143 ± 10
Candesartan (0.1mg/kg) 142 ± 10
Ang-(1-7) and candesartan 142 ± 9
Ang-(1-7), candesartan, and PD123319 (50µg/kg/min) 137 ± 9
Group 5 (n = 8)
Ang-(1-7) (15pmol/kg/min) 128 ± 11
Candesartan (0.1mg/kg) 122 ± 10
Ang-(1-7) and candesartan 133 ± 5
Ang-(1-7), candesartan, and A779 (15pmol/kg/min) 132 ± 2
Group 6 (n = 8)
Ang-(1-7) (15pmol/kg/min) 129 ± 5
Candesartan (0.01mg/kg) 126 ± 10
Ang-(1-7) and candesartan 132 ± 6
Ang-(1-7), candesartan, and A779 (15pmol/kg/min) 125 ± 8
Values are ± SEM.
Compound 21 [14]. Furthermore, the AT2R antagonist,
PD123319, but not the MasR antagonist, A779, blocked this
vasodepressor eﬀect of Ang (1-7) [11].
While it is well recognized that the renin-angiotensin
system (RAS) has a critical role in the cardiovascular system;
its role in the aging process is still under investigation.
During aging, circulating levels of Ang II are downregulated
while local production of Ang II is increased in the aorta
and other vessels [15] suggesting an essential role of local
RAS in the vasculature during aging. However, there is little
functional evidence about angiotensin receptors and their
role during aging. In this context, we have shown that AT2R
expression was increased in both endothelial and vascular
smooth muscle of aortae obtained from aged WKY rats [16].
Given that there was an increased vascular AT2Re x p r e s -
sion in aging [16], the current study was designed to test
our hypothesis that AT2R-mediated depressor function was
preserved with aging. In the present study, we have used
Ang (1-7) as an endogenous ligand for the AT2R, as we
have previously reported in adult rats [11]. In preliminary
experiments, we have determined that vascular expression
of both AT2Ra n dMasR/ACE2 axis was upregulated with
aging. Therefore, this strategy of using Ang (1-7) will also
determine whether or not there was a role for MasRt oe v o k e
vasodepressor eﬀects with aging.
2. Methods
2.1. Animals. All animal care and experimental procedures
were approved by the Monash University Animal Ethics
Committee and performed according to the guidelines of the
National Health and Medical Research Council of Australia
for animal experimentation.
16- to 18-week-old WKY male rats (300 to 350g) and
20-month-old WKY male rats (450–500g) were obtained
from the Animal Resource Centre (Perth, Wash, USA) and
were used to represent adult and aged normotensive rats,
respectively. Animals were maintained on a 12-hour day/
night cycle with standard laboratory rat chow and water
available ad libitum.International Journal of Hypertension 3
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Figure 1: Eﬀect of the AT1R Ang (1-7) (15pmol/kg/min; 4-hour infusion depicted by full line), AT1R antagonist, candesartan (0.01mg/kg
bolus IV; depicted by an arrow), saline (0.1mL/kg 0.9% NaCl IV for 4 hours), and Ang (1-7) + candesartan on MAP in (a) adult WKY rats
(n = 4) and (b) aged WKY rats (n = 7). Values represent mean ± SEM. ∗∗∗P<0.001, for treatment eﬀect of Ang (1-7) + candesartan versus
all other treatments (2-way RM ANOVA).
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Figure 2: Eﬀect of Ang (1-7) (15pmol/kg/min; 4-hour infusion depicted by full line), AT1R antagonist, candesartan (0.1mg/kg bolus IV;
depicted by an arrow), Ang (1-7) + candesartan, and Ang (1-7) + candesartan + AT2R antagonist, PD123319 (50µg/kg/min for 2 hours;
depicted by dashed line), on MAP in (a) adult WKY rats (n = 6) and (b) aged WKY rats (n = 7). Values represent mean ± SEM. ∗P<0.05;
∗∗P<0.01; ∗∗∗P<0.001, for treatment eﬀect of Ang (1-7) + candesartan versus all other treatments as indicated (2-way RM ANOVA).
2.2. In Vivo Procedures. Rats were anesthetised (ketamine
and xylazine; 75mg/kg and 10mg/kg, i.p, resp.; supple-
mented as required). Two catheters were inserted into the
right jugular for intravenous drug administration. A catheter
was implemented into the right carotid artery for direct
blood pressure measurement as described previously [11–
14]. Rats were housed in individual cages and allowed free
access to food and water while maintained on 12-hour day/
night cycle. The arterial catheter was infused overnight with
heparinised saline using an infusion pump.
24 hours after the surgery, the arterial catheter was at-
tached to a pressure transducer (Gould Inc), connected to a
MacLab-8dataacquisitionsystem(ADInstruments,Sydney),
interfaced to a Macintosh computer. Mean arterial pressure4 International Journal of Hypertension
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Figure 3: Eﬀect of Ang (1-7) (15pmol/kg/min; 4-hour infusion depicted by full line), AT1R antagonist, and candesartan in (a) adult WKY
rats (0.1mg/kg bolus IV; depicted by an arrow) and (b) aged WKY rats (0.01mg/kg bolus IV; depicted by an arrow), together with Ang
(1-7) + candesartan and Ang (1-7) + candesartan + MasR antagonist A779 (15pmol/kg/min for 2 hours; depicted by dashed line), on MAP
(n = 8 for both groups). Values represent mean ± SEM. (a) ∗∗∗P<0.001, for treatment eﬀect of Ang (1-7) + candesartan versus Ang (1-7)
or candesartan alone (2-way RM ANOVA), † <0.05; ††† <0.001, for treatment eﬀect of Ang (1-7) + candesartan +A779 versus candesartan
or Ang (1-7) alone (2-way RM ANOVA). (b) ∗∗P<0.01; ∗∗∗ <0.001 for treatment eﬀect of Ang (1-7) + candesartan versus Ang (1-7),
candesartan, or Ang (1-7) + candesartan + A779 (2-way RM ANOVA).
(MAP) and heart rate (HR) were computed from the phasic
blood pressure signal.
2.3. Experimental Protocol. Rats received drug combinations
in a randomised fashion over a 4-day protocol, as we have
performed previously [11, 12, 14]. Doses for candesartan
and PD123319 were chosen on the basis of previous studies
[11, 12, 14]. Six groups of rats underwent experimental
protocols during which basal MAP and HR were recorded.
Adult and aged WKY rats (Groups 1 and 2, resp.) were
randomized to receive the following treatments on diﬀerent
days: (1) candesartan (0.01mg/kg), (2) Ang (1-7) infusion
(15pmol/kg per minute for 4 hours), (3) Ang (1-7) infu-
sion together with candesartan, and (4) a 4-hour infusion
(0.1mL/kg per hour IV) of saline (0.9% NaCl) to conﬁrm a
lack of eﬀect on MAP. Animals in Group 3 (adult WKY rats)
and Group 4 (aged WKY rats) were randomized to receive
the following treatments: (1) candesartan at a 10-fold higher
dose (0.1mg/kg), (2) Ang (1-7) infusion (15pmol/kg per
minute for 4 hours), (3) Ang (1-7) infusion together with
candesartan, and (4) Ang (1-7) infusion in the presence of
candesartan and PD123319 infusion (50µg/kg per minute
for 2 hours). In analogous experiments in additional adult
and aged WKY rats (Groups 5 and 6), the putative Ang (1-7)
antagonist, A779 (15pmol/kg per minute), was used instead
of PD123319. Doses of Ang (1-7) and A779 are based on our
previous study [11].
2.4. Localization of ACE2, AT1,A T 2,a n dM a sR e c e p t o r s .
Localization of ACE2, AT1,A T 2,a n dMas receptors using
immunoﬂuorescence was performed using thoracic aortic
sections taken from na¨ ıve aged and adult rats to determine
changes in expression levels between the two age groups.
Male adult and aged WKY rats were killed by isoﬂurane
inhalation followed by decapitation, and the thoracic aorta
was removed in order to dissect 3–5mm long sections.
Immunoﬂuorescence was performed using 10µm thick
section of thoracic aorta cut on Cryostat. Aortic sections
were incubated overnight at 4◦C with 1/500 dilution of
polyclonal rabbit antibodies raised against AT1R, AT2R,
MasR, and ACE2. Following overnight incubation, sections
wereincubatedfor2.5hourwithagoatanti-rabbitsecondary
antibody conjugated with Alexa 568 ﬂurophore. Rabbit
IgG antibody was used as negative control. Sections were
mounted with antifade medium (VectorShield) and cover
slipped. Sections were imaged using Olympus Fluoview
500 confocal microscope equipped with a krypton/argon
laser. Fluorescence intensity was quantiﬁed using analysis
professional software (Soft Imaging System, Singapore) with
identical measurement settings.
2.5. Statistical Analysis. All data are presented as mean
responses ± standard error of the mean (SEM). Diﬀerences
in MAP between treatments were analysed using a 2-way
ANOVA repeated measure analysis of variance. Diﬀerences
in ﬂuorescence intensity were analysed using 1-way ANOVA
with Bonferroni corrections where appropriate. Statistical
analysis was performed using GraphPad Prism (Version
5.0c). P values <0.05 were deemed statistically signiﬁcant.International Journal of Hypertension 5
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Figure 4: (a) Representative immunolocalisation images of AT1R, AT2R, MasR, and ACE2 in adult WKY rats and aged WKY rats. Mean data
for aortic expression of the (b) AT1R, (c) AT2R, (d) MasR, and (e) ACE2 expressed as relative ﬂuorescent units in adult (n = 5) and aged
(n = 4) WKY rats. ∗∗∗P<0.001 versus adult WKY rats.
2.6. Materials. PD123319 and candesartan were kind gifts
from Pﬁzer and AstraZeneca, respectively. All other chem-
icals were purchased from commercial sources: ketamine
(Troy Laboratories, Australia), xylazine (Troy Laboratories),
isoﬂurane (Baxter, USA), Ang (1-7) (Ausep, Australia),
A779(Auspep,Australia),rabbitpolyclonalantibodiesraised
against AT1R, AT2R, and ACE2 (Santa Cruz Biotechnology
Inc., Catalogue no. SC1173, SC9040, and SC2099), rabbit
polyclonal antibody raised against MasR (Novus Biologicals,
USA, Catalogue no. NLS1531), secondary goat anti-rabbit
Alexa 568 antibody (Invitrogen, USA, Catalogue no. A-
21069).6 International Journal of Hypertension
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Figure 5: Ratios of (a) AT2R:A T 1R, (b) MasR:A T 1R, and (c) ACE2:AT1Ri na d u l ta n da g e dW K Yr a t s .∗∗P<0.01; ∗∗∗P<0.001 versus
adult WKY rats.
3. Results
3.1. In Vivo Eﬀect of Ang (1-7) in Conscious Normotensive
Rats. Basal MAPs of WKY rats over the 4 experimental days
for each group are listed in Table 1. There was no signiﬁcant
diﬀerence between resting MAPs over the experimental
period for any of the treatment groups, suggesting that none
of the acute treatments had long-lasting eﬀects and, there-
fore, did not inﬂuence baseline MAP on subsequent days.
In groups 1 and 2, infusion of saline had no signiﬁcant
eﬀect on MAP (Figure 1). Therefore, this treatment was
not performed in subsequent groups in order to include
additional treatment arms. In all groups, infusion of Ang
(1-7) (15pmol/kg/min) or candesartan (0.01 or 0.1mg/kg
IV) had no signiﬁcant eﬀect on MAP. Coinfusion of Ang
(1-7) and candesartan (0.01mg/kg IV) had no eﬀect on
MAP in adult WKY rats (Figure 1(a))w h e r e a s ,i na g e dW K Y
rats, combined administration of Ang (1-7) and candesartan
(0.01mg/kg IV) signiﬁcantly decreased MAP (P<0.001)
(Figure 1(b)). When Ang (1-7) was combined with a 10-
fold higher dose of candesartan (0.1mg/kg IV), there were
signiﬁcant reductions in MAP in both adult and aged WKY
male rats compared with Ang (1-7) alone or candesartan
alone (P<0.01). Moreover, this depressor eﬀect of Ang
(1-7) was abolished by the addition of the AT2R antagonist,
PD123319 (50µg/kg/min), (Figures 2(a) and 2(b)).
In separate groups of animals, we examined the ability of
theMasRantagonistA779tomodifytheAng(1-7)-mediated
depressor eﬀect. Coinfusion of the Ang (1-7) antagonist
A779 with the Ang (1-7)/candesartan combination in adult
WKY male rats did not aﬀect Ang (1-7)-mediated depressor
response (Figure 3(a)). By contrast, the Ang (1-7)-evoked
depressorresponse,duringAT1Rblockade,inagedWKYrats
was in fact abolished by the addition of A779 (Figure 3(b)).
3.2. Localization of ACE2, AT1,A T 2,a n dM a sR e c e p t o r s .
Expression levels of ACE as well as angiotensin levels were
determined using thoracic sections taken from na¨ ıve adult
WKY rats (n = 5) and aged WKY rats (n = 4). ACE2,
AT1R, AT2R, and MasR were all localised throughout the
entire aortic sections (Figure 4(a)). Expression levels of the
AT1R were not changed between adult and aged WKY male
rats, whereas ACE2, AT2R, and MasR expression levels wereInternational Journal of Hypertension 7
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Figure 6: Schema depicting diﬀerential mechanisms of Ang (1-7)-mediated vasodepressor eﬀect in adult and aged candesartan-treated rats.
AT1R expression was similar in aortae from adult and aged rats whereas there was upregulation of AT2R, MasR, and ACE2. Therefore, a
lower level of AT1R blockade with candesartan (X) was required in aged animals (b) compared with adult animals (a) in order to unmask
the vasodilator axis. MasR was not functionally active in adult rats.
all signiﬁcantly upregulated in aged WKY rats compared
to adult WKY rats (Figures 4(b)–4(e)). Therefore, when
expressedrelativetoAT1Rlevels,eachofthevasodilatornon-
AT1R components of the RAS was signiﬁcantly increased in
aged WKY rats compared to adult WKY rats (Figure 5).
4. Discussion
The main ﬁndings of the current study demonstrate for the
ﬁrst time that the depressor eﬀect evoked by Ang (1-7) is
preserved in aged normotensive candesartan-treated animals
and was sensitive to both AT2Ra n dMasR blockade which
contrasts with the involvement of only AT2R in the eﬀects
of Ang (1-7) in adult candesartan-treated rats. Moreover,
these ﬁndings were consistent with increased AT2R, MasR,
and ACE2 expression in the thoracic aorta of aged WKY rats.
AT2R-mediated relaxation is a well-established eﬀect in
isolated resistance vessels [17–21]. Previous studies have
shown AT2R-mediated vasodilatation in adult conscious
rats [11–14, 22]. The AT2R-mediated reduction in blood
pressure was likely to be a result of direct vasodilatation,
rather than a result of decrease in cardiac output, as
CGP42112 increased mesenteric and renal conductance in
SHR, which was indicative of regional vasodilatation [13].
Furthermore, it is well documented that, in order to unmask
any AT2R-mediated vasodilatation, there needs to be a
r e m o v a lo fat o n i cA T 1R-mediated vasoconstriction induced
by endogenous Ang II [23].
In the current study, acute Ang (1-7) infusion against
ab a c k g r o u n do fA T 1R blockade resulted in a decrease in
MAP in adult WKY male rats, and this Ang (1-7) response
was mediated exclusively via AT2R in adult WKY male rats
since the AT2R antagonist, PD123319, abrogated this Ang
(1-7)-depressor response, which is consistent with previous
ﬁndings obtained in both SHR and WKY rats [11]. Of
note, the Ang (1-7) antagonist, A779, failed to inhibit
vasodepressor responses induced by Ang (1-7) during AT1R
blockade in adult rats, which conﬁrmed our previous study
that also found a 10-fold higher dose of A779 failed to block
Ang(1-7)[11].Thus,atleastinthisadultmodel,anexclusive
role for Ang (1-7) as an endogenous ligand for the AT2Rw a s
demonstrated.
In contrast, in the aged setting, the vasodepressor eﬀect
of Ang (1-7) was mediated by both AT2Ra n dM a s R
stimulation. Moreover, both candesartan doses (0.01 and
0.1mg/kg) were eﬀective in unmasking Ang (1-7)-mediated
vasodepressor responses in aged rats. These results are
consistent a 10-fold lower dose of candesartan being used
to reveal Ang (1-7)-mediated vasodepressor eﬀects via AT2R
in SHR compared with WKY rats [11] and point towards
an increased sensitivity to AT1R blockade in aged rats, as8 International Journal of Hypertension
we have noted previously [24]. Increased vascular expression
of AT2R in aging was seen in mesenteric resistance arteries
[25] and in thoracic aorta [16]. Thus, Ang (1-7) infusion
reduced MAP via AT2R in aged WKY rats irrespective of the
background dose of candesartan. However, there are numer-
ous reports suggesting the MasR as the functional bind-
ing site for Ang (1-7) [7]. For example, Peiro et al. (2007),
observed comparable impairment in Ang (1-7)-mediated
vasorelaxation as a result of pharmacologic or genetic in-
hibition of MasR using A779 and MasR-deﬁcient mice, res-
pectively [26]. However, Ang (1-7) evoked vasorelaxation
in pig coronary arteries that was attenuated by the AT2R
antagonist,PD123319,suggestinganAT2Rin v olv ement[27].
Subsequent studies conﬁrmed that Ang (1-7) can mediate
its eﬀects via AT2R[ 8–10]. Ang (1-7)-stimulated NO release
in bovine aortic endothelial cells was markedly attenuated
by AT2R inhibition (∼90%) [28, 29] and to a lesser extent
by MasR inhibition (∼50%) [28], suggesting activation of
multiple receptors by Ang (1-7) which is also consistent
with Ang (1-7)-stimulated arachidonic acid release in rabbit
vascular smooth muscle cells [30].
More recently, we have demonstrated that chronic treat-
ment with Ang(1-7) was both vaso- and atheroprotective in
Apolipoprotein E-deﬁcient mice via both MasRa n dA T 2R
[31]. Similarly, in the current study, we found that Ang (1-
7) evoked a vasodepressor responses in aged candesartan-
treated rats that was sensitive to both the AT2R antagonist
PD123319 and the MasR antagonist A779. This ﬁnding
suggests that, unlike that in adult normotensive rats, Ang (1-
7) can act via AT2R and/or MasR during aging. Therefore,
we also examined relative expression levels of the AT1R,
AT2R, and MasR as well as ACE2 to determine if this could
account for the age-related diﬀerences in the cardiovascular
eﬀects of Ang (1-7). We have now conﬁrmed an increased
AT2R expression in aortae from aged WKY rats [16], and in
addition we have shown, for the ﬁrst time, a marked increase
inexpressionlevelsofbothMasRandACE2inaorticsections
from aged WKY rats. Future studies will need to conﬁrm
these ﬁndings using RT-PCR. These changes in ATR subtype
expression ﬁt with our in vivo results and also with other
evidence for increased AT2R function in aging. For exam-
ple, PD123319 can potentiate AT1R-mediated contractions,
which is an indirect measure of AT2R relaxation [32, 33],
and this “PD123319 potentiation” was enhanced in human
coronary microvessels and was positively correlated with age
[34]. To our knowledge, there are no reported functional
correlates for enhanced Ang (1-7) in aging. At the same
time, there was no diﬀerence in the expression levels of AT1R
between adult and aged WKY rats, although a lower level
of the AT1R block was required to unmask the depressor
eﬀect of Ang (1-7) in aged rats. One possible explanation for
this diﬀerence between aged and adult WKY rats is due to
the presence of several potential vasodilator pathways (AT2R,
MasR) resulting in preserved vasodilatation in aged WKY
rats. This hypothesis is strengthened by the increased ratio of
non-AT1RcomponentstoAT1RinagedWKYrats(Figure 6).
In conclusion we have found that Ang (1-7)-mediated
vasodepressor activity is preserved with aging. Thus, we can
postulate that an increased AT2R/MasR/ACE2 vasodilator
axis relative to AT1R in aged rats is in part responsible for
the ability of Ang (1-7) to operate via multiple mechanisms
in aging, as opposed to only AT2R in adult normotensive
candesartan-treated rats.
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